GSK posts higher profits but indicates sales growth to slow in 2026 - It came amid the first set of results by new chief executive Luke Miels, who took over from Emma Walmsley at the turn of the year.

GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics RAPT for an estimated aggregate equity value of $2.2 billion. The impending ...

LONDON (Reuters) -GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit growth, lifting the British company's shares by nearly 7% to ...

GSK posted higher profit as sales for its specialty treatments including HIV, cancer and asthma beat expectations, offsetting lower vaccine sales on weak demand in the U.S. GSK plans to bring five new ...

GSK's 2024 results are strong, with a promising shift toward specialty medicines, particularly in HIV, respiratory conditions, and cancer, driving long-term growth. Key drugs Blenrep and Depemokimab ...

GSK said it is confident of achieving the top end of its full-year guidance after posting an increase in sales and profit for the second quarter, mainly driven by the strong performance of its ...

Reversing a policy introduced five years ago after a marketing scandal, GlaxoSmithKline will resume payments to physicians who help promote its drugs next year, according to Bloomberg. 1. The British ...

GSK beat profit expectations in the fourth quarter, driven by demand for its HIV drugs and Asthma medicine.

GSK’s profit rose on better-than-expected performance of HIV, cancer and asthma treatments, offsetting lower vaccine demand in the U.S. GSK plans to bring five new specialty medicines to market this ...

GSK GSK-1.70%decrease; red down pointing triangle raised its sales and earnings forecasts for the year after its specialty medicines business helped lift sales in the third quarter, the last reporting ...